Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Cue Biopharma Inc (CUE)
Cue Biopharma Inc (CUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 95,210
  • Shares Outstanding, K 45,123
  • Annual Sales, $ 1,250 K
  • Annual Income, $ -53,010 K
  • 60-Month Beta 2.05
  • Price/Sales 23.02
  • Price/Cash Flow N/A
  • Price/Book 2.19
Trade CUE with:

Options Overview Details

View History
  • Implied Volatility 61.00% ( -40.13%)
  • Historical Volatility 81.96%
  • IV Percentile 6%
  • IV Rank 13.04%
  • IV High 410.38% on 11/10/23
  • IV Low 8.59% on 08/15/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 60
  • Volume Avg (30-Day) 216
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 7,372
  • Open Int (30-Day) 6,412

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.29
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.34
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +21.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.95 +3.59%
on 02/23/24
2.58 -21.71%
on 02/12/24
-0.43 (-17.55%)
since 02/02/24
3-Month
1.95 +3.59%
on 02/23/24
3.25 -37.83%
on 12/08/23
-0.59 (-22.61%)
since 12/04/23
52-Week
1.70 +18.82%
on 10/23/23
5.12 -60.55%
on 05/10/23
-0.91 (-31.06%)
since 03/03/23

Most Recent Stories

More News
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

Cue Biopharma, Inc. (CUE) delivered earnings and revenue surprises of 12.12% and 37.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CUE : 2.02 (-4.27%)
ARMP : 4.12 (+1.23%)
Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates

Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LUMO : 3.00 (unch)
CUE : 2.02 (-4.27%)
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.51% and 8.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for...

DCPH : 16.61 (-4.32%)
CUE : 2.02 (-4.27%)
Cue Biopharma Reports Second Quarter 2022 Financial Results

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 2.02 (-4.27%)
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 2.02 (-4.27%)
Cue Biopharma to Present at the Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 2.02 (-4.27%)
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 2.02 (-4.27%)
AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

ABCL : 5.00 (-0.99%)
CUE : 2.02 (-4.27%)
Cue Biopharma Reports First Quarter 2022 Financial Results

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 2.02 (-4.27%)
Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates

Intercept (ICPT) delivered earnings and revenue surprises of 34.83% and 2.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ICPT : 19.00 (+0.21%)
CUE : 2.02 (-4.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 2.19
2nd Resistance Point 2.14
1st Resistance Point 2.08
Last Price 2.02
1st Support Level 1.97
2nd Support Level 1.92
3rd Support Level 1.86

See More

52-Week High 5.12
Fibonacci 61.8% 3.81
Fibonacci 50% 3.41
Fibonacci 38.2% 3.01
Last Price 2.02
52-Week Low 1.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar